IP Library Granted Patent US 10,793,565
Granted Patent B2
US 10,793,565 · App. 16/296,563 · Granted Oct 6, 2020

Heterocyclic compounds as immunomodulators

Inventors: Liangxing Wu (Wilmington, DE); Bo Shen (Garnet Valley, PA); Meizhong Xu (Hockessin, DE); Wenqing Yao (Chadds Ford, PA)
Assignee: Incyte Corporation
C07D471/04A61P37/00A61P37/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,793,565
App. No.
16/296,563
Granted
Oct 6, 2020
Kind
B2
Abstract

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Claims (16)

1. A compound which is N-(3′-(8-chloro-6-((2-hydroxyethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2,2′-dimethylbiphenyl-3-yl)-5-((2-hydroxyethylamino)methyl)picolinamide, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipient or carrier.

3. The compound of claim 1 , wherein the compound is N-(3′-(8-chloro-6-((2-hydroxyethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2,2′-dimethylbiphenyl-3-yl)-5-((2-hydroxyethylamino)methyl)picolinamide.

4. A pharmaceutical composition comprising the compound of claim 3 , and one or more pharmaceutically acceptable excipient or carrier.

5. A compound which is N-(2-chloro-3′-(8-chloro-6-((2-hydroxyethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2′-methylbiphenyl-3-yl)-5-((2-hydroxyethylamino)methyl)picolinamide, or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipient or carrier.

7. The compound of claim 5 , wherein the compound is N-(2-chloro-3′-(8-chloro-6-((2-hydroxyethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2′-methylbiphenyl-3-yl)-5-((2-hydroxyethylamino)methyl)picolinamide.

8. A pharmaceutical composition comprising the compound of claim 7 , and one or more pharmaceutically acceptable excipient or carrier.

9. A compound which is N-(2-chloro-3′-(8-cyano-6-((2-hydroxyethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2′-methylbiphenyl-3-yl)-5-((2-hydroxyethylamino)methyl)picolinamide, or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising the compound of claim 9 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipient or carrier.

11. The compound of claim 9 , wherein the compound is N-(2-chloro-3′-(8-cyano-6-((2-hydroxyethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2′-methylbiphenyl-3-yl)-5-((2-hydroxyethylamino)methyl)picolinamide.

12. A pharmaceutical composition comprising the compound of claim 11 , and one or more pharmaceutically acceptable excipient or carrier.

13. A compound which is 2-((8-chloro-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)biphenyl-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)methylamino)ethanol, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising the compound of claim 13 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipient or carrier.

15. The compound of claim 13 , wherein the compound is 2-((8-chloro-2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)biphenyl-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)methylamino)ethanol.

16. A pharmaceutical composition comprising the compound of claim 15 , and one or more pharmaceutically acceptable excipient or carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2019
From: WU, LIANGXING; SHEN, BO; XU, MEIZHONG; YAO, WENQING
To: INCYTE CORPORATION
Reel/Frame 049871/0006 →
Continuity (4)
Continuation 15850221 · Dec 21, 2017
Provisional Application 62487341 · Apr 19, 2017
Provisional Application 62438001 · Dec 22, 2016
Related Publication 20190202824A1 · Jul 4, 2019
Cited By (6)
US 12,187,743 US 12,247,026 US 12,247,038 US 12,404,272 US 12,466,822 US 12,516,044